[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100492982":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":61,"collaborators":63,"id":67,"slug":26,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":26,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":26,"enrollmentInfo":75,"targetDuration":26,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":26,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"University of New Mexico","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Variable amplitude","EXPERIMENTAL","Individualized amplitude",[13],"Device: Soterix Medical Incorporated 4x1 adapter",{"label":15,"type":16,"description":17,"interventionNames":18},"Fixed amplitude","ACTIVE_COMPARATOR","Fixed (800 milliamperes) amplitude",[19],"Device: Traditional ECT device",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Soterix Medical Incorporated 4x1 adapter","Device permits individualized amplitudes",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Traditional ECT device","FDA approved ECT device with fixed amplitude.",[15],[32],{"name":33,"affiliation":5,"role":34},"Chris Abbott, MD","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","5052720406","cabbott@salud.unm.edu",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},"Megan Lloyd, MS","‭(505) 272-3507‬","meglloyd@salud.unm.edu",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"University of New Mexico Health Science Center","RECRUITING","Albuquerque","New Mexico","87110","United States",{"type":53,"coordinates":54},"Point",[55,56],-106.65114,35.08449,{"lat":56,"lon":55},[59],{"name":33,"role":37,"phone":60,"phoneExt":26,"email":39},"505-272-2223",{"type":62,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[64],{"name":65,"class":66},"National Institute of Mental Health (NIMH)","NIH","100492982",false,"NCT05699226","Amplitude Titration to Improve ECT Clinical Outcomes","Amplitude Titration to Improve ECT Clinical Outcomes Randomized Clinical Trial","Inclusion Criteria:\n\n* Diagnosis of major depressive disorder or bipolar II\n* Clinical indications for ECT with right unilateral electrode placement\n\nExclusion Criteria:\n\n* Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease)\n* Other psychiatric conditions (e.g., schizophrenia, bipolar I disorder)\n* Current drug or alcohol use disorder (except for nicotine)\n* Contraindications to MRI.","ALL","50 Years",{"count":76,"type":77},50,"ESTIMATED","INTERVENTIONAL",[80],"NA","A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT:\n\nH1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2).\n\nH2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency",[83,84,85],"Depression","ECT","Cognitive Change","2026-01-23",{"date":88,"type":89},"2026-01-26","ACTUAL",{"date":91,"type":89},"2023-09-14",{"date":93,"type":77},"2028-01-01",{"name":5,"class":6},1]